Moll Law Group - Current Cases - NuvaRing

Popular birth control product NuvaRing has been linked to an increased risk of blood clots that may lead to heart attack, stroke or sudden death. Released in 2001, NuvaRing has become so popular that it is now the most widely used non-pill contraceptive in the world. Made from flexible plastic, NuvaRing is inserted directly into a woman's vagina and delivers a low-dose combination of progestin and estrogen into a woman's bloodstream.

In one of the clinical trials of NuvaRing a healthy woman in her twenties developed a blood clot. Despite the clinical trial's concerning results, Merck ultimately manufactured Nuvaring without including this alarming information in the drug's fineprint or marketing materials. Reported side effects with the device include blood clots, deep vein thrombosis, heart attack and death among many others. On February 7, 2014, Merck announced an agreement to pay $100 million to over 3,800 claimants.

Moll Law Group
22 W Washington St
15th Floor
Chicago, IL 60602
Phone: [phone]